Literature DB >> 6309565

Temperature-dependent regulation of d-cis-[3H]diltiazem binding to Ca2+ channels by 1,4-dihydropyridine channel agonists and antagonists.

H Glossmann, T Linn, M Rombusch, D R Ferry.   

Abstract

The binding of the Ca2+-channel blocker d-cis-[3H]diltiazem to guinea pig skeletal muscle microsomes is temperature-dependent. At 2 degrees C the KD is 39 nM and Bmax is 11 pmol/mg protein. The binding is fully reversible (K -1 = 0.02 min -1). The binding sites discriminate between the diastereoisomers l- and d-cis-diltiazem, reconize verapamil, gallopamil and tiapamil, and are sensitive to La3+-inhibition. At 30 degrees C the KD is 37 nM and the Bmax is 2.9 pmol/mg protein. D-cis-diltiazem-labelling is regulated by the 1,4-dihydropyridine Ca2+-channel blockers and a novel Ca2+-channel activator in a temperature-dependent manner. At 30 degrees C an enhancement of d-cis-diltiazem binding by the channel blockers is observed. This is attributed to a Bmax increase. EC50-values for enhancement and the maximal enhancement differ for the individual 1,4-dihydropyridines. At 2 degrees C 1,4-dihydropyridines inhibit d-cis-[3H]diltiazem binding. This is attributed to a Bmax decrease. We have directly labelled one of the drug receptor sites within the Ca2+-channel which can allosterically interact with the 1,4-dihydropyridine binding sites.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6309565     DOI: 10.1016/0014-5793(83)80972-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

Review 1.  The molecular pharmacology and structural features of calcium channels.

Authors:  D R Ferry; A Goll; M Rombusch; H Glossmann
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

2.  High affinity interaction of mibefradil with voltage-gated calcium and sodium channels.

Authors:  P Eller; S Berjukov; S Wanner; I Huber; S Hering; H G Knaus; G Toth; S D Kimball; J Striessnig
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

Review 3.  Molecular basis of drug interaction with L-type Ca2+ channels.

Authors:  J Mitterdorfer; M Grabner; R L Kraus; S Hering; H Prinz; H Glossmann; J Striessnig
Journal:  J Bioenerg Biomembr       Date:  1998-08       Impact factor: 2.945

4.  Repeated cocaine treatment enhances HIV-1 Tat-induced cortical excitability via over-activation of L-type calcium channels.

Authors:  T Celeste Napier; Lihua Chen; Fatah Kashanchi; Xiu-Ti Hu
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-25       Impact factor: 4.147

5.  Inotropic effects of Ca2+ channel agonist and antagonists in neuraminidase-treated left atria of rats.

Authors:  Y Hattori; S Hazama; M Kanno; Y Nakao
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

Review 6.  Calcium channels: molecular pharmacology, structure and regulation.

Authors:  M M Hosey; M Lazdunski
Journal:  J Membr Biol       Date:  1988-09       Impact factor: 1.843

7.  125I-iodipine, a new high affinity ligand for the putative calcium channel.

Authors:  D R Ferry; H Glossmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

8.  Interactions between a "calcium channel agonist", Bay K 8644, and calcium antagonists differentiate calcium antagonist subgroups in K+-depolarized smooth muscle.

Authors:  M Spedding; C Berg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-11       Impact factor: 3.000

9.  Characterization of [3H]-nitrendipine binding to uterine smooth muscle plasma membrane and its relevance to inhibition of calcium entry.

Authors:  S Batra
Journal:  Br J Pharmacol       Date:  1985-08       Impact factor: 8.739

10.  Dihydropyridine-sensitive Ca2+ channels in mammalian skeletal muscle cells in culture: electrophysiological properties and interactions with Ca2+ channel activator (Bay K8644) and inhibitor (PN 200-110).

Authors:  C Cognard; G Romey; J P Galizzi; M Fosset; M Lazdunski
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.